Regeneron Pharmaceuticals Inc at Wells Fargo Healthcare Conference Transcript
Thank you very much for joining us today. My name is Mohit Bansal. I'm one of the biopharma analysts here at Wells Fargo. And with us next, we have the Regeneron management team with us. We have Bob Landry, the CFO of the company; Ryan Crowe, the Head of IR of the company. Thank you very much, Bob and Ryan, for joining us. And with that, I'll hand it over to you, Bob.
Okay. Ryan, why don't you open up with an FLS?
Absolutely. So today's discussion may contain forward-looking statements, which may contain -- actual results may differ from those forward-looking statements. A discussion of our risks and uncertainties may be found in our SEC disclosure documents. And any forward-looking statements, we're not obligated to update them at any time.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |